PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Certoparin→

Certoparin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
9005-49-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Low-molecular-weight heparin (LMWH)antithrombin-dependent anticoagulant
Mechanism of action
Binds antithrombin and accelerates inhibition of coagulation factor Xa, with less activity against thrombin (factor IIa) than unfractionated heparin, reducing fibrin formation and thrombus propagation.
Indications / reported uses
  • Prevention of venous thromboembolism in surgical and selected medical patients at risk, and treatment of thromboembolic conditions in countries where certoparin is authorised; product-specific dosing and availability apply

Sources: NLM MeSH — Certoparin · PubMed — Certoparin low-molecular-weight heparin · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Certoparin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Certoparin Permitted Daily Exposure (PDE) report (the Certoparin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Certoparin Occupational Exposure Limit (OEL) report (the Certoparin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.